Please review our Terms & Conditions before purchasing.
Tomio K, Kawana K, Taguchi A, Isobe Y, Iwamoto R, Yamashita A, et al
No patients receiving GLP-1 RAs were excluded due to loss of follow-up, while 8 patients (0.2%) who did not receive GLP-1 RAs were excluded for this reason (Supplemental Table 3)
In clinical studies, participants taking semaglutide GLP-1 lost more weight on average than those taking liraglutide or other GLP-1 medications
This product is not intended to treat, mitigate, diagnose or cure any disease
To address that gap, CMS launched a temporary Medicare GLP-1 Bridge program: starting July 1, 2026, eligible beneficiaries can access certain GLP-1 medications for about $50 per month, with eligibility tied to BMI thresholds (for example, a BMI of 35 or higher, or 27 or higher with other clinical criteria)